Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Growth Needs Resuscitation, But Medtronic Still Looks Like A Value

The biggest obstacle for med-tech giant Medtronic (NYSE:MDT) today is not its competition nor the still-sleepy markets for medical procedures. Instead, the biggest problem Medtronic has is a market/investor base that seems unwilling to accept the company for what it is. Medtronic came in shy of the more robust growth expectations this quarter, but even modest long-term growth projections suggest these shares are undervalued today.

Fiscal Q3 Comes In Evenly Light

At least a few sell-side analysts had been trying to make the case that this would be the quarter where Medtronic would make the turn and re-establish good mid-single digit organic growth credentials. That didn't come to pass, though, as Medtronic had a pretty "meh" quarter across...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details